IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Merck & Co., Inc.

Q1 2026 Holdings

Filed 2026-05-13 | 14 holdings | $349.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Moderna Inc(MRNA)COM60770K107$117.3M2,308,19033.6%
Personalis Inc(PSNL)COM71535D106$89.5M14,044,94325.6%
Kymera Therapeutics Inc(KYMR)COM501575104$64.3M772,16518.4%
Entrada Therapeutics IncCOM29384C908$22.0M1,739,7686.3%
Eikon Therapeutics Inc(EIKN)COM282564103$17.6M1,666,6665.0%
Aktis Oncology Inc(AKTS)COM01021M104$17.0M952,8444.9%
Alector Inc(ALEC)COM014442107$7.6M3,545,7192.2%
Sutro Biopharma IncCOM869367102$6.8M272,3511.9%
Evaxion Biotech A/SSPONSORED ADS29970R204$4.5M1,214,1261.3%
Viridian Therapeutics Inc(VRDN)COM92790C104$1.8M93,4140.5%
Xilio Therapeutics Inc(XLO)COM98422T209$891.3K105,9820.3%
Carisma Therapeutics Inc(CARM)COM14216R101$47.9K1,473,2400.0%
Neuphoria Therapeutics Inc(NEUP)COM64136E102$40.8K10,0270.0%
Tuhura Biosciences(HURA)COM898920103$34.8K19,4450.0%